Your browser doesn't support javascript.
loading
The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial.
Karkeet, Riham M; Zekri, Abdelrahman N; Sayed-Ahmed, Mohamed M; Sherif, Ghada M; Salem, Salem E; Abdelbary, Ahmed; Fouad, Mariam A; Saad, Sherif Y.
Afiliación
  • Karkeet RM; Pharmacology and Experimental Oncology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
  • Zekri AN; Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
  • Sayed-Ahmed MM; Pharmacology and Experimental Oncology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
  • Sherif GM; Biostatistics and Cancer Epidemiology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
  • Salem SE; Medical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
  • Abdelbary A; Department of Surgical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt.
  • Fouad MA; Pharmacology and Experimental Oncology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
  • Saad SY; Moleculat Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, United States of America.
PLoS One ; 17(12): e0278282, 2022.
Article en En | MEDLINE | ID: mdl-36480560

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Inhibidores de Hidroximetilglutaril-CoA Reductasas / Rosuvastatina Cálcica Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans / Male País/Región como asunto: Africa Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2022 Tipo del documento: Article País de afiliación: Egipto

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Inhibidores de Hidroximetilglutaril-CoA Reductasas / Rosuvastatina Cálcica Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans / Male País/Región como asunto: Africa Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2022 Tipo del documento: Article País de afiliación: Egipto